Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06314854
Other study ID # P202300046
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 15, 2023
Est. completion date March 15, 2024

Study information

Verified date April 2024
Source Kirklareli University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is known that being in nature and the visual perception of nature positively affects an individual's mood and self-confidence. Studies have reported that natural sounds have a positive effect in situations such as pain, anxiety, and stress. This finding means that listening to natural sounds may be a simple and easily accessible intervention that can positively impact key human stress systems. Although many non-pharmacological methods are used in the literature to reduce the invasive pain and anxiety experienced by hemodialysis (HD) patients during cannulation, the most popular recently; However, we aimed to determine the effect of the sound of running water, which we have not yet encountered in dialysis patients, on invasive pain and anxiety experienced during fistula access.


Description:

In this study; Between 15 December 2023 and 15 March 2024, patients receiving dialysis will be included in the Dialysis Service of two hospitals in western of Turkey which havedialysis for 3 days a week. The sample calculation was determined using power analysis based on a previous study. (Çetinkaya, Karabulut (2010). The sample size of the study was calculated as at least 30 patients, for each group that met the sampling criteria. The population of the research was determined as 74 people. The number of patients who met the inclusion criteria was 68, and these patients were assigned to the experimental (34 patients) and control (34 patients) groups by an independent statistician with the help of a computer program (randomizer.org). Patients over the age of 18, who are volunteers, who undergo dialysis 3 days a week, who do not have any communication problems and who do not use any psychiatric medication will be included in the study. Patients who do not meet the inclusion criteria will be excluded from the study. Dialysis sessions are held 3 days a week, between 08.00-16.00, on Mon-Wed-Fri and Tuesday-Thurs-Sat. All patients who volunteer to participate in the study will be included in the study. During the cannulation process, the experimental group will listen to the sound of flowing water throughout the process with the help of the researcher's smartphone. VAS scale will be applied to the experimental and control groups after each cannulation, and the State and Trait Anxiety Scale will be applied before the first dialysis session and after the 12th session. The control group will receive standard care. A total of 12 sessions will be followed in both groups.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date March 15, 2024
Est. primary completion date March 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - between 18 - 65 years - not have communication problem - Patients receiving dialysis 3 days a week - Have cannulation Exclusion Criteria: - under 18- over 65 years - Have communication problems - Not have dialysis 3 days a week - Have not cannulation

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Running water sound
Running water sound for experimental group Standard care for control group

Locations

Country Name City State
Turkey Aas Kirklareli Center

Sponsors (1)

Lead Sponsor Collaborator
Kirklareli University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Assessment VAS nearly 40 days
Secondary State and Trait Anxiety Assessment STAI I AND STAI II nearly 40 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06382701 - Effect of Aromatherapy on Pain, Anxiety and Satisfaction in Cannulation N/A
Completed NCT04674930 - Effects of Exercise Program on Physical Functioning of Hemodialysis Patients. N/A
Recruiting NCT02245633 - Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients N/A
Recruiting NCT01970280 - Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Phase 4
Completed NCT06165211 - Nature-Based Sound Application For Hemodialysis Patients N/A
Completed NCT06106763 - Mandala Colouring On Anxiety, Depression, Pain And Quality of Life N/A
Completed NCT05693584 - The Effect of Using Virtual Reality Glasses on Pain During Fistula Cannulation in Hemodialysis Patients N/A
Completed NCT01932853 - Association Between Dose Dialysis by Kt and Mortality N/A
Completed NCT01273974 - The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients Phase 2/Phase 3
Completed NCT04139759 - THE EFFECT OF HAND AND FOOT MASSAGE ON FATIGUE IN HEMODIALYSIS PATIENTS N/A
Not yet recruiting NCT05574595 - Effect on Pain and Comfort Associated With Fistula Puncture N/A
Completed NCT04175652 - Effects of Laughter Yoga on Hemodialysis Patients' Plasma-Beta Endorphin Levels, Pain Levels and Sleep Quality N/A
Not yet recruiting NCT06314243 - The Impact of Pumpkin Seed Oil Supplementation on Hemodialysis Patients Phase 3
Completed NCT01596842 - Effect of Omega-3 Fatty Acid on Vitamin D Activation Phase 4
Enrolling by invitation NCT01896882 - Dietary Sodium Restriction in Hemodialysis Patients N/A
Completed NCT00638300 - Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD) N/A
Terminated NCT00259714 - Dialysate Sodium Individualization in Hemodialysis Phase 1
Completed NCT01846754 - Prevalence of Fatigue in Hemodialysis Patients N/A
Completed NCT00491868 - Clinical Study of R744 to Hemodialysis Patients Phase 3
Completed NCT04195919 - The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients Phase 1